• Studies from several European countries have shown that the total societal costs of caring for patients with Alzheimer's disease (AD) vary across countries and regions. 1, 2 • Differences between countries and regions in healthcare system structure and resource availability have a direct impact on resource utilization and costs.
• Some data on resource utilization in AD in Europe exist, 2 but few studies have examined resource use in multiple countries, included a large sample size and prospective follow-up, used standardized measures of resource use, or included the full range of AD severities. 1,2 • GERAS was a prospective cohort study conducted in France, Germany and the UK, designed to evaluate resource use and costs associated with AD for community-dwelling patients and their caregivers. 3 • Baseline data from GERAS showed that resource use and costs increased with AD severity. 3 ISPOR 20 th Annual European Congress; Milan, Italy; Nov 7 -11, 2015
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CONCLUSIONS
• The 18-month GERAS study showed differences between France, Germany and the UK in resource utilization for AD. -These differences resulted in between-country differences in the total societal costs of AD.
• Caregiver time was consistently the main contributor to 18-month total societal costs.
• It is difficult to assess how differences in resource utilization contributed to the overall cost differences between countries.
-However, some of the between-country differences in caregiver time could be explained by differing use of community care services and institutionalization.
• Other differences in resource use across countries reflect country-specific health and social care systems, but had limited influence on differences in total societal costs.
• To compare drivers of societal costs for AD over 18 months in three European countries (France, Germany and the UK), using prospectively collected data from GERAS. 
OBJECTIVE Study Design
• GERAS was an 18-month, multicenter, prospective, non-interventional cohort study conducted in France, Germany and the UK. 3 • Eligible patients were community-dwelling patients with probable AD 4 presenting during the course of normal clinical care. 
LIMITATIONS
• Our analyses of resource use are only applicable to community-dwelling patients and cannot be extended to patients living permanently in long-term care.
• Resource use was collected at each visit via interview with the caregiver, so may be subject to recall bias. • We only analyzed time spent providing informal care by the primary caregiver, which may result in the underestimation of informal caregiving time, as it is possible that AD patients receive care from several family members.
METHODS
Resource Use Estimates
• Data on patient and caregiver resource use were captured using the Resource Utilization in Dementia (RUD) instrument. 6 • Caregiver time was recorded as time spent on assisting the patient with basic activities of daily living (ADL; e.g. eating, bathing, dressing, using the bathroom), instrumental ADL (e.g. housework, shopping, medication use, financial management), and supervision (i.e. preventing dangerous events, such as risks of fire, walking onto a road alone, walking outside without appropriate clothing).
• All baseline resource use was measured as activity in the previous month.
• At each 6-month visit resource use was measured as activity in:
-The previous month for caregiver time -The previous 3 months for community care services and outpatient visits -The previous 6 months for hospitalizations and other resource use items. • To enable cross-country comparisons, a weighted score for all community care services and all outpatient visits was calculated by multiplying the individual resource item by the average of the unit costs for the three countries, and then summing the weighted value.
Cost Estimates
• Monthly costs were estimated for each country by applying unit costs of services and products (2010 values) to the health and community care resource use data collected over the 18-month follow-up period. 3 -Monthly costs included the cost of temporary or permanent institutionalization. -A zero cost value was applied to caregiver supervision time.
• UK costs in pounds sterling (£) were converted to Euros (€) using the conversion rate £1=€1.1661, calculated as the average monthly exchange rate for 2010. 3 • Total societal costs for each country were calculated using an opportunity cost approach taking into account productivity loss for working caregivers and lost leisure time for non-working caregivers.
• Total societal costs were calculated by adding patient healthcare costs, patient social care costs, and caregiver informal care costs.
Statistical Models
• Models for differences in resource use between countries were analyzed for each resource use item, and adjusted for (in addition to country): patient age, patient gender, MMSE severity group (mild, moderate, MS/S), number of patient comorbidities, baseline total ADL score, caregiver age, caregiver relationship (spouse, yes/no), caregiver working for pay and baseline score for the resource use item. • Country differences for each resource use item were analyzed by repeated measures models of resource use at each 6-month visit.
• Least squares (LS) mean estimates and 95% confidence intervals (CI) are presented by country from each model. • Data from generalized linear models (GLM) with gamma distribution and loglink function (caregiver time, 3-month weighted scores for community care services and outpatient visits) are presented as LS means.
• Data from logistic regression models (temporary accommodation, AD medication, financial support received) are presented as odds ratios (OR); an OR >1 represents an increased likelihood of that outcome compared with the UK (reference country).
• Data from zero-inflated negative binomial distribution models (caregiver missing work days, patient hospital stays, individual items for community care services and outpatient visits) are presented as OR for having the event, and the LS means of those having the event.
• Data from proportional hazards models (time to institutionalization) are presented as hazard ratios (HR). (Figure 1 ).
RESULTS
Baseline characteristic
• Caregiver time spent on basic and instrumental ADL was the largest component of total societal costs in all three countries (range: 53.8% in France to 64.8% in the UK).
• The six resource use items with the greatest contribution to total costs in each country are shown in Table 2 .
• Caregivers in France and Germany spent significantly less time on instrumental ADL than caregivers in the UK (Figure 2 ). • Caregiver time spent on supervision did not differ between countries.
• Patients in France used more community care services than patients in Germany or the UK (Figure 3) . France or Germany (Figure 3 ). • The number of hospital stays and use of AD medication did not differ between countries (Table 3 ).
• Patients in the UK were significantly more likely to receive financial support than patients in France or Germany (Table 3 ). 
